論文

査読有り
2018年4月1日

The anti-human cytomegalovirus drug tricin inhibits cyclin-dependent kinase 9

FEBS Open Bio
  • Hidetaka Sadanari
  • ,
  • Kazuhiro J. Fujimoto
  • ,
  • Yuto Sugihara
  • ,
  • Tomoki Ishida
  • ,
  • Masaya Takemoto
  • ,
  • Tohru Daikoku
  • ,
  • Tsugiya Murayama

8
4
開始ページ
646
終了ページ
654
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1002/2211-5463.12398
出版者・発行元
Wiley Blackwell

4′,5,7-trihydroxy-3′,5′-dimethoxyflavone (tricin), derived from Sasa albo-marginata, has been reported to suppress significantly human cytomegalovirus (HCMV) replication in human embryonic lung (HEL) fibroblast cells. However, the target protein of tricin remains unclear. This study focused on the anti-HCMV activity of tricin in terms of its binding affinity to cyclin-dependent kinase 9 (CDK9). A molecular docking study predicted that tricin binds well to the ATP-binding site of CDK9. Experimental measurements then revealed that tricin inhibits the kinase activity of CDK9 and affects the phosphorylation of the carboxy-terminal domain of RNA polymerase II. Based on these results, we conclude that CDK9 is one of the target proteins of tricin. We also found that tricin possesses anti-HCMV activity with no cytotoxicity against HEL cells.

リンク情報
DOI
https://doi.org/10.1002/2211-5463.12398
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/29632816
ID情報
  • DOI : 10.1002/2211-5463.12398
  • ISSN : 2211-5463
  • PubMed ID : 29632816
  • SCOPUS ID : 85042175990

エクスポート
BibTeX RIS